Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 601–700 of 1,000
Restifo, L. L. (2005) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20083 · Cited by 37
“Three biochemical approaches to modulating HD pathology have similar beneficial effects in rodent and Drosophila models [Steffan et al., 2001; Hockly et al., 2003; Ravikumar et al., 2004; Steffan et al., 2004].”
Polyglutamine Disease: Acetyltransferases Awry
Hughes, R. E. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00709-1 · Cited by 40
“In a transgenic Drosophila model, progressive neurodegeneration and early adult lethality caused by expanded polyQ expression were arrested by feeding flies HDAC inhibitors, either butyrate or suberoylanilide hydroxamic acid (SAHA) [14].”
Beglopoulos, V., & Shen, J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.010 · Cited by 35
Targeting Histone Deacetylases for the Treatment of Huntington's Disease
Gray, S. G. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00184.x · Cited by 36
“The first indications that HDAC inhibitors may prove useful in the treatment of Huntingtons came from yeast and fly models where treatments of HD models were found arrest neurodegeneration or mitigated the effects on affected gene promoters [9,39].”
BackgroundTea, J. S., Chihara, T., & Luo, L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1643-10.2010 · Cited by 34
“For instance, inhibition of HDACs can improve memory in mouse models of neurodegenerative diseases (Fischer et al., 2007) and can reduce polyglutaminedependent neurodegeneration in Drosophila (Steffan et al., 2001).”
BackgroundHwang, Y. J., Han, D., Kim, K. Y., Min, S., Kowall, N. W., Yang, L., Lee, J.-H., Kim, Y., & Ryu, H. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1041 · Cited by 37
Metabolism in Huntington’s disease: a major contributor to pathology
Singh, A., & Agrawal, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00844-y · Cited by 35
MicroRNA editing patterns in Huntington’s disease
Guo, S., Yang, J., Jiang, B., Zhou, N., Ding, H., Zhou, G., Wu, S., Suo, A., Wu, X., Xie, W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06970-6 · Cited by 35
Wang, C., Eessalu, T. E., Barth, V., Mitch, C. H., Wagner, F. F., Hong, Y., Neelamegam, R., Schroeder, F. A., Holson, E. B., Haggarty, S. J., et al. (2013) · Europe PMC (PubMed Central) · Cited by 39
Emerging drug therapies in Huntington's disease
Mason, S., & Barker, R. A. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902918299 · Cited by 36
“Several of the transcription factors mentioned above have some involvement in histone deacetylation [111,113]; as such, histone modifying enzymes have been considered as a therapeutic approach in HD.”
BackgroundThe completed human genome: implications for chemical biology
Austin, C. P. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00083-8 · Cited by 35
“Inhibitorsofhistonedeacetylases(HDACs) have been suggested as clinical treatments for cancer and neurodegenerative disorders [38], but broad-spectrum HDAC inhibitors such as trichostatin also inhibit tubulin acetylation, making interpretation of the cellular effects of non-specific HDAC inhibitors complex; development…”
BackgroundThe interplay between microRNAs and histone deacetylases in neurological diseases
Bourassa, M. W., & Ratan, R. R. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.03.012 · Cited by 35
Drug targeting of dysregulated transcription in Huntington's disease
Kazantsev, A. G., & Hersch, S. M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.02.005 · Cited by 36
“The concept of altered histone acetylation in HD was proposed and tested by Leslie Thompson and co-workers (Steffan et al., 2001).”
MethodSelf-citationKoike, M., Fukushi, J., Ichinohe, Y., Higashimae, N., Fujishiro, M., Sasaki, C., Yamaguchi, M., Uchihara, T., Yagishita, S., Ohizumi, H., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.099283 · Cited by 41
Popiel, H. A., Burke, J. R., Strittmatter, W. J., Oishi, S., Fujii, N., Takeuchi, T., Toda, T., Wada, K., & Nagai, Y. (2011) · Journal of Amino Acids · doi:10.4061/2011/265084 · Cited by 32
“of the expanded polyQ protein [33–36].”
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases
Markouli, M., Strepkos, D., Chlamydas, S., & Piperi, C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101968 · Cited by 35
Drosophila as a Tool for Personalized Medicine: A Primer
Kasai, Y., & Cagan, R. L. (2010) · Personalized Medicine · doi:10.2217/pme.10.65 · Cited by 37
“Other researchers have reported compound screens against fly models of neuro-degenerative diseases such as triplet-repeat based diseases and Parkinson’s [66–84].”
BackgroundBiological Roles of Prion Domains
Inge-Vechtomov, S., Zhouravleva, G., & Chernoff, Y. (2007) · Prion · doi:10.4161/pri.1.4.5059 · Cited by 33
Sekiya, M., Akiko, M.-O., Hearn, S., Sakakibara, Y., Fujisaki, N., Suzuki, E., Ando, K., & Iijima, K. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.05.019 · Cited by 37
“In these models, Sin3A loss of function confers protective effects by restoring histone acetylation levels to normal levels (Kontopoulos et al., 2006; Steffan et al., 2001).”
BackgroundLiu, C., Hou, W., Li, S., & Tsao, R. (2020) · Journal of Separation Science · doi:10.1002/jssc.201901252 · Cited by 33
Tagawa, K., Hoshino, M., Okuda, T., Ueda, H., Hayashi, H., Engemann, S., Okado, H., Ichikawa, M., Wanker, E. E., & Okazawa, H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02372.x · Cited by 37
Dwivedi, V., Tripathi, B. K., Mutsuddi, M., & Lakhotia, S. C. (2013) · Cited by 43
Identification of Human Proteins That Modify Misfolding and Proteotoxicity of Pathogenic Ataxin-1
Petrakis, S., Raskó, T., Russ, J., Friedrich, R. P., Strödicke, M., Riechers, S., Muehlenberg, K., Möller, A., Reinhardt, A., Vinayagam, A., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002897 · Cited by 38
“In the last decade a number of proteins have been reported to influence misfolding and aggregation of polyQ-containing disease proteins in model systems like yeast, worm or flies [17–26].”
BackgroundPerspectives on gene therapy in myotonic dystrophy type 1
Magaña, J. J., & Cisneros, B. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22551 · Cited by 39
“A similar strategy based on high-throughput screening of chemicals has been successfully employed in Huntington’s disease to identify molecules that inhibit polyglutamine aggregation and/or toxicity in different models, such as Drosophila, transgenic mice, and neuronal cell lines (Wellington et al., 2000; Heiser et al…”
BackgroundSmall-Molecule Chromatin-Modifying Agents: Therapeutic Applications
Mai, A. (2010) · Epigenomics · doi:10.2217/epi.10.7 · Cited by 35
Polyglutamine androgen receptor-mediated neuromuscular disease
Giorgetti, E., & Lieberman, A. P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2275-1 · Cited by 33
“neuronal dysfunction and ameliorates motor phenotype in cellular and animal models of polyglutamine repeat diseases [65–68].”
Epigenetic modulation by small molecule compounds for neurodegenerative disorders
Singh, A. K., Halder-Sinha, S., Clement, J. P., & Kundu, T. K. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.014 · Cited by 31
The Tiny Drosophila Melanogaster for the Biggest Answers in Huntington’s Disease
Rosas‐Arellano, A., Estrada‐Mondragón, A., Piña, R., Mantellero, C. A., & Castro, M. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082398 · Cited by 36
“Additionally, the soluble Pcaf protein is altered in Httex1pQ93 flies and the mutant htt expression is not reduced; taken together, these results indicate that the reduction of Pcaf has a significant impact on HD pathology, however, therapeutic strategies to elevate the Pcaf levels are ineffective in ameliorating HD p…”
BackgroundMethodProtein phosphatase 1 regulates huntingtin exon 1 aggregation and toxicity
Branco‐Santos, J., Herrera, F., Poças, G. M., Pires‐Afonso, Y., Giorgini, F., Domingos, P. M. D. N., & Outeiro, T. F. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx260 · Cited by 33
Novel therapeutic targets for Huntington’s disease
Hannan, A. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.639 · Cited by 34
“The accumulating evidence for a role of transcriptional dysregulation in HD pathogenesis (outlined above) is supported by recent drug studies suggesting that histone acetylation is a potential therapeutic target in HD [51,52].”
BackgroundIijima‐Ando, K., Wu, P., Drier, E. A., Iijima, K., & Yin, J. C. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503937102 · Cited by 46
Ebbel, E. N., Leymarie, N., Schiavo, S., Sharma, S., Gevorkian, S., Hersch, S. M., Matson, W. R., & Costello, C. E. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.01.010 · Cited by 32
Mallik, M., & Lakhotia, S. C. (2010) · Genetics · doi:10.1534/genetics.109.113696 · Cited by 37
“This in turn would suppress IB formation and restore histone acetylation and transcriptional regulation in cells expressing the mutant poly(Q) proteins (Steffan et al. 2001; Taylor et al. 2003; Li and Li 2004; Iijima-Ando et al. 2005).”
BackgroundWang, L., & Qin, Z. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00410.x · Cited by 36
Dominant ataxias and Friedreich ataxia: an update
Albin, R. L. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084230.82329.d5 · Cited by 40
Walcott, J. L., & Merry, D. E. (2002) · Vitamins and hormones · doi:10.1016/s0083-6729(02)65062-9 · Cited by 34
Using Drosophila models of Huntington's disease as a translatable tool
Lewis, E. A., & Smith, G. A. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.07.026 · Cited by 37
Thakur, T., Sharma, S., Kumar, K., Deshmukh, R. R., & Sharma, P. L. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.035 · Cited by 31
“…in cyclic nucleotide levels has been observed in Huntington′s disease patients (Cramer et al., 1984) and inhibition of CREB-mediated transcription has been hypothesized to contribute to neuronal loss in Huntington′s disease (Jiang et al., 2003; Nucifora et al., 2001; Steffan et al., 2000, 2001).”
BackgroundRawat, V., Goux, W. J., Piechaczyk, M., & D’Mello, S. R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9058-1 · Cited by 32
Pharmacological protein targets in polyglutamine diseases: Mutant polypeptides and their interactors
Margulis, B. A., Vigont, V. A., Lazarev, V. F., Kaznacheyeva, E. V., & Guzhova, I. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.022 · Cited by 40
Vernizzi, L., Paiardi, C., Licata, G., Vitali, T., Santarelli, S., Raneli, M., Manelli, V., Rizzetto, M., Gioria, M., Pasini, M. E., et al. (2020) · Cells · doi:10.3390/cells9010196 · Cited by 32
“This model recapitulates the cellular and molecular events described in HD, including the loss of neurons and impaired animal motility [17].”
Beaver, M., Bhatnagar, A., Panikker, P., Zhang, H., Snook, R., Parmar, V., Vijayakumar, G., Betini, N., Akhter, S., & Elefant, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-75035-3 · Cited by 36
Khyati, Malik, I., Agrawal, N., & Kumar, V. (2020) · Chronobiology International · doi:10.1080/07420528.2020.1842752 · Cited by 31
Wang, Y., Lin, F., & Qin, Z. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-1118-6 · Cited by 38
Gonzales, E. R., Chen, H., Munuve, R. M., Mehrani, T., Nadel, A., & Koustova, E. (2008) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e31818233ef · Cited by 32
“Lifespan extension by pharmacological inhibitors of HDAC is accompanied by hyperacetylation on the tails of H3 and H4 specifically, and changes in gene expression.(28,29) It has been proposed that different acetylation patterns of the core histones induced by various classes of HDAC determine the intensity of transcri…”
BackgroundTargeting Huntington’s disease through histone deacetylases
Gray, S. G. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0025-7 · Cited by 34
“For instance, mutant Htt protein was quickly shown to form a complex with the lysine acetyltransferases KAT3A (CBP) and KAT2B (P/CAF; Nucifora et al. 2001; Steffan et al. 2001, 2000; Kazantsev et al. 1999).”
BackgroundInfluentialEpigenetic drugs in the treatment of skeletal muscle atrophy
Guasconi, V., & Puri, P. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282fa1810 · Cited by 34
A Huntingtin Peptide Inhibits PolyQ-Huntingtin Associated Defects
Arribat, Y., Bonneaud, N., Talmat-Amar, Y., Layalle, S., Parmentier, M., & Maschat, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068775 · Cited by 38
“We first analyzed the rescuing activity of P42 on eye toxicity generated in flies expressing either 128Q-hHtt [21], (containing the P42 sequence; Figures 7B, S1) or a short 93Q-hHtt [19] that does not include the P42 sequence (Figures 7C, S1).”
BackgroundMethodInfluentialKlevytska, A. M., Tebbenkamp, A. T. N., Savonenko, A. V., & Borchelt, D. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181d6c436 · Cited by 34
“caused by expression of mutant htt exon 1 and decreased lethality in Drosophila that expresses mutant htt fragments (11).”
BackgroundMoily, N. S., Ormsby, A. R., Stojilovic, A., Ramdzan, Y. M., Diesch, J., Hannan, R. D., Zajac, M. S., Hannan, A. J., Oshlack, A., & Hatters, D. M. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.07.004 · Cited by 35
“Furthermore, CREB signalling has been suggested to be mediated by deactivation of CREB binding protein (CREBBP) activity through abnormal interactions with soluble Httex1 (Steffan et al., 2001; Jiang et al., 2006; Schaffar et al., 2004; Cong et al., 2005).”
BackgroundModeling Tauopathy in the Fruit Fly Drosophila melanogaster
Khurana, V. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15403 · Cited by 34
“In the polyglutamine neurodegenerative disease field, the demonstration of histone deacetylase inhibitors being effective in arresting neurodegeneration based on analogous findings in the fly has been an important proof-of-principle [22,61].”
BackgroundFonte, C., Grenier, J., Trousson, A., Chauchereau, A., Lahuna, O., Baulieu, É.-É., Schumacher, M., & Massaad, C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506930102 · Cited by 35
Vanommeslaeghe, K., Alsenoy, C. V., Proft, F. D., Martins, J. C., Tourwé, D., & Geerlings, P. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b304707e · Cited by 36
Polyglutamine tract binding protein-1 is an intrinsically unstructured protein
Takahashi, M., Mizuguchi, M., Shinoda, H., Aizawa, T., Demura, M., Okazawa, H., & Kawano, K. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.03.001 · Cited by 31
Siomi, H., Ishizuka, A., & Siomi, M. C. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20011 · Cited by 35
“Furthermore, building on years of experience, a number of fly researchers are also using Drosophila as a model for designing new therapeutic strategies for treating human diseases [Steffan et al., 2001; Kazantsev et al., 2002; Auluck et al., 2002].”
BackgroundSoliman, M. L., Ohm, J. E., & Rosenberger, T. A. (2013) · Lipids · doi:10.1007/s11745-013-3799-x · Cited by 30
“An increase in histone acetylation also reduces oxidative stress-induced apoptosis [35], polyglutamine toxicity in a mouse motor neuron–neuroblastoma fusion cell line [36] and in Drosophila models of polyglutamine diseases [37].”
BackgroundThe Fruit Fly, Drosophila melanogaster: Modeling of Human Diseases (Part II)
Allocca, M., Zola, S., & Bellosta, P. (2018) · InTech eBooks · doi:10.5772/intechopen.73199 · Cited by 35
Alzheimer's Disease: The Quest to Understand Complexity
Marques, S., Oliveira, C. R., Outeiro, T. F., & Pereira, C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100303 · Cited by 34
Transgenic Animal Models of Huntington’s Disease
Yang, S., & Chan, A. W. S. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_105 · Cited by 32
Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA)
Katsuno, M., Adachi, H., Inukai, A., & Sobue, G. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072860 · Cited by 35
Gong, B., Kielar, C., & Morton, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041450 · Cited by 30
“It is also possible that proteins other than Htt containing a poly(Gln) sequence are ubiquitinated and recruited during aggregate formation [72,73,74,75,76].”
BackgroundProtective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy
Butchbach, M. E. R., Lumpkin, C. J., Harris, A. W., Saieva, L., Edwards, J. D., Workman, E., Simard, L. R., Pellizzoni, L., & Burghes, A. H. M. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.009 · Cited by 33
“…al., 2009; Petri et al., 2006; Ryu et al., AC C EP TE D M AN U SC R IP T 2005)), Alzheimer disease (Ribobaraza et al., 2009), Huntington disease (Ferrante et al., 2003; Gardian et al., 2005; Steffan et al., 2001), stroke (Qi et al., 2004) and dentatorubralpallidoluysian atrophy (Ying et al., 2006).”
InfluentialSodium dodecyl sulfate‐insoluble oligomers are involved in polyglutamine degeneration
Wong, A. S. L., Chan, W. M., & Chan, H. Y. E. (2008) · The FASEB Journal · doi:10.1096/fj.07-103887 · Cited by 30
Gene expression and behaviour in mouse models of HD
Bowles, K. R., Brooks, S. P., Dunnett, S. B., & Jones, L. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.07.021 · Cited by 32
Regulating the Ubiquitin/Proteasome Pathway Via cAMP-signaling: Neuroprotective Potential
Huang, H., Wang, H., & Figueiredo‐Pereira, M. E. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9628-2 · Cited by 31
Subramanian, K., Rauniyar, N., Lavallée‐Adam, M., Yates, J. R., & Balch, W. E. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.064949 · Cited by 34
“Indeed, multiple studies have shown that HDACis are effective in treating inherited diseases caused by misfolding of many proteins (69, 70).”
BackgroundElek, G. Z., Koppel, K., Zubrytski, D. M., Konrad, N., Järving, I., Lopp, M., & Kananovich, D. G. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03305 · Cited by 32
Flies as the ointment: Drosophila modeling to enhance drug discovery
Bell, A. J., McBride, S. M. J., & Dockendorff, T. C. (2009) · Fly · doi:10.4161/fly.3.1.7774 · Cited by 30
Varadarajan, S., Breda, C., Smalley, J. L., Butterworth, M., Farrow, S. N., Giorgini, F., & Cohen, G. M. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.1 · Cited by 33
“The w;+;UAS HTT93Q exon 1 flies were a gift from Larry Marsh and Leslie Thompson (University of California, Irvine, Irvine, CA, USA).(34) Reagents and antibodies.”
MethodDevelopment of Histone Deacetylase Inhibitors as Therapeutics for Neurological Disease
Gottesfeld, J. M., & Pandolfo, M. (2009) · Future Neurology · doi:10.2217/fnl.09.55 · Cited by 32
“Studies in cell culture, yeast, Drosophila and, more recently, mouse models of polyQ disease, have indicated that HDACIs might provide a useful class of agents to ameliorate the transcriptional deficits in HD and some of the SCAs [69–72].”
BackgroundEmerging chemotherapeutic strategies for Huntington’s disease
Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 29
“The administration of HDAC inhibitors, which act to inhibit histone deacetylases and enhance transcription locally, lowers the levels of acetylated histones, ameliorates the clinical symptoms and neuropathology in mouse models of HD, and reduces lethality in HD Drosophila [70,72,113].”
BackgroundInfluentialMolecular Pathogenesis of Spinocerebellar Ataxia Type 1 Disease
Kang, S., & Hong, S. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0095-y · Cited by 32
Deutsch, S. I., Rosse, R. B., Long, K. D., Gaskins, B. L., Burket, J. A., & Mastropaolo, J. P. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.11.004 · Cited by 32
“To date, therapeutic administration of histone deacetylase inhibitors is undergoing clinical trials for malignancy and neurodegenerative diseases, such as Huntington disease (Steffan et al., 2001; Ferrante et al., 2003; Minamiyama et al., 2004; Gardian et al., 2005; Monneret, 2005; Ryu et al., 2005; Ying et al., 2006).”
BackgroundInfluentialSurvival Motor Neuron (SMN) Protein Interacts with Transcription Corepressor mSin3A
Zou, J., Barahmand-Pour, F., Blackburn, M. L., Matsui, Y., Chansky, H. A., & Yang, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309218200 · Cited by 29
Twyning, M. J., Tufi, R., Gleeson, T. P., Kolodziej, K. M., Campesan, S., Terriente-Félix, A., Collins, L., Lazzari, F. D., Giorgini, F., & Whitworth, A. J. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113681 · Cited by 32
Mallik, M., & Lakhotia, S. C. (2010) · Journal of Genetics · doi:10.1007/s12041-010-0072-4 · Cited by 30
HDAC inhibitors rescue multiple disease-causing CFTR variants
Anglès, F., Hutt, D. M., & Balch, W. E. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz026 · Cited by 28
Histone deacetylase in neuropathology
Gupta, R. V., Ambasta, R. K., & Kumar, P. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.09.004 · Cited by 33
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice
Hecklau, K., Mueller, S. G., Koch, S., Mehkary, M., Kilic, B., Harms, C., Boehm‐Sturm, P., & Yildirim, F. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.616886 · Cited by 30
Management of altered metabolic activity in Drosophila model of Huntington’s disease by curcumin
Aditi, K., Singh, A., Shakarad, M., & Agrawal, N. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211046927 · Cited by 29
“Expression of polyglutamine (polyQ) containing peptides was carried out using the bipartite UAS-GAL4 expression system.(39) Virgins from stocks with polyQ constructs under the control of yeast UAS were crossed with males from driver line expressing yeast GAL4 transcriptional activator under neuronal elav promotor.”
MethodZhang, L., Liu, Y., Lu, Y., & Wang, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115295 · Cited by 29
The Role of Epigenetics in Neurodegenerative Diseases
Lovrei, L., Maver, A., Zadel, M., & Peterli, B. (2013) · InTech eBooks · doi:10.5772/54744 · Cited by 37
Tamura, T., Horiuchi, D., Chen, Y., Sone, M., Miyashita, T., Saitoe, M., Yoshimura, N., Chiang, A., & Okazawa, H. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1319-10.2010 · Cited by 30
“HDAC inhibitors are known to activate transcription and restore the normal phenotype in some model animals of polyglutamine diseases, in which transcriptional disturbance has been implicated (McCampbell et al., 2001; Steffan et al., 2001; Hockly et al., 2003; Minamiyama et al., 2004).”
BackgroundKnock-down of PQBP1 impairs anxiety-related cognition in mouse
Ito, H., Yoshimura, N., Kurosawa, M., Ishii, S., Nukina, N., & Okazawa, H. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp378 · Cited by 30
Animal models in biomedical research: Relevance of Drosophila melanogaster
Obafemi, T. O., Ayeleso, A. O., Adewale, O. B., Unuofin, J. O., Ekundayo, B. E., Ntwasa, M. M., & Lebelo, S. L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41605 · Cited by 34
“They also discovered that HDAC inhibitors reversed the observed neurodegeneration in flies and may be relevant in slowing or preventing progressive neurodegeneration observed in HD and other polyQ-associated diseases [175].”
Planar cell polarity gene Fuz triggers apoptosis in neurodegenerative disease models
Chen, Z. S., Li, L., Peng, S. I., Chen, F. M., Zhang, Q., An, Y., Lin, X., Li, W., Koon, A. C., Chan, T., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745409 · Cited by 30
“Fly lines UAS:: ATXN3fl-Q27/Q84 [27], gmr::Gal4 [72] and UAS::Httexon1-Q93 [73] were described previously.”
Singh, M. D., Raj, K., & Sarkar, S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.015 · Cited by 30
Acinus integrates AKT1 and subapoptotic caspase activities to regulate basal autophagy
Nandi, N., Tyra, L. K., Stenesen, D., & Krämer, H. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201404028 · Cited by 33
“…codon within the 40-bp insertion; Laundrie et al., 2003; gift from K. McCall, Boston University, Boston, MA), UAS-htt-exon1-Q93 (expresses Huntington's disease exon1 peptide with 93 glutamines under UAS control; Steffan et al., 2001 ; gift from T. Neufeld, University of Minnesota , Saint Paul, MN).”
Protective role of Engrailed in a Drosophila model of Huntington's disease
Mugat, B., Parmentier, M., Bonneaud, N., Chan, H. Y. E., & Maschat, F. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn255 · Cited by 30
Chemical probes targeting epigenetic proteins: Applications beyond oncology
Ackloo, S. Z., Brown, P. J., & Müller, S. (2017) · Epigenetics · doi:10.1080/15592294.2017.1279371 · Cited by 30
Song, W., Zsindely, N., Faragó, A., Marsh, J., & Bodai, L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx432 · Cited by 26
Self-citationEpigenetic Signaling in Glia Controls Presynaptic Homeostatic Plasticity
Wang, T., Morency, D. T., Harris, N., & Davis, G. W. (2019) · Neuron · doi:10.1016/j.neuron.2019.10.041 · Cited by 27
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition
Shi, Y., Gerritsma, D. A., Bowes, A. J., Capretta, A. A., & Werstuck, G. H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.006 · Cited by 35
Messer, A. C., & McLear, J. A. (2006) · BioDrugs · doi:10.2165/00063030-200620060-00002 · Cited by 53
Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease
Esteves, S., Duarte‐Silva, S., Naia, L., Neves‐Carvalho, A., Teixeira‐Castro, A., Rego, A. C., Silva‐Fernandes, A., & Maciel, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141610 · Cited by 27
Green tea infusion alleviates neurodegeneration induced by mutant Huntingtin inDrosophila
Varga, J., Dér, N. P., Zsindely, N., & Bodai, L. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1484021 · Cited by 29
Self-citationThe Bdnf and Npas4 genes are targets of HDAC3-mediated transcriptional repression
Titus, A. S. C. L. S., Sharma, D., Kim, M. S., & D’Mello, S. R. (2019) · BMC Neuroscience · doi:10.1186/s12868-019-0546-0 · Cited by 27
Histone deacetylase-3: Friend and foe of the brain
D’Mello, S. R. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220928278 · Cited by 27
“The first indication that HDACs contribute to neurodegenerative disease came from a study by Steffan et al.(37) in 2001 which showed that pharmacological inhibition of HDACs suppressed polyglutamine-dependent neurotoxicity in Drosophila (Table 2).”
Backgroundα-Synuclein A53T Binds to Transcriptional Adapter 2-Alpha and Blocks Histone H3 Acetylation
Lee, J.-Y., Kim, H., Jo, A., Khang, R., Park, C., Park, S.-J., Kwag, E., & Shin, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105392 · Cited by 29
Mani, S., Jindal, D., & Singh, M. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220328142427 · Cited by 36
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.